LOR-2040 is currently in an advanced Phase II clinical study in patients with relapsed or refractory acute myeloid leukemia.
To provide an adequate supply of LOR-2040 for ongoing and projected clinical trials, Lorus said that it has already secured additional supply of LOR-2040 from Avecia Biotechnology, a private biotechnology company focused on the development and manufacture of innovative medicines.
Aiping Young, president and CEO of Lorus, said: “Orphan drug status, together with our broad patent coverage achieved for this drug in the European Union, has served to strengthen and align our proprietary European market position with the level we have achieved in the US.”